Our preliminary research has found that G-Rh2 can potentially serve as an inhibitor of PDK4, thereby inhibiting tumor glycolysis, promoting mitochondrial oxidative phosphorylation, contributing to the benign transformation of tumors, and inducing tumors to enter the normal apoptotic program. The gene discussed is PDK4; the disease is neoplasm.